| P2093 | author name string | Bénédicte Stengel | |
| | Guillaume Geri | |
| | Marie Metzger | |
| | Jean-Jacques Boffa | |
| | Jean-Philippe Haymann | |
| | Eric Thervet | |
| | Pascal Houillier | |
| | François Vrtovsnik | |
| | Martin Flamant | |
| | Emmanuelle Vidal-Petiot | |
| | Anne-Laure Faucon | |
| | NephroTest study group | |
| P2860 | cites work | Management of hypertension in chronic kidney disease | Q85657232 |
| | Aldosterone antagonists for preventing the progression of chronic kidney disease | Q24194979 |
| | Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study | Q33837171 |
| | Dietary sodium in chronic kidney disease: a comprehensive approach | Q34063442 |
| | Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study | Q35504141 |
| | Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases | Q36079020 |
| | Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis | Q36127484 |
| | Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). | Q36158003 |
| | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial | Q36305422 |
| | Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study | Q36463881 |
| | Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials | Q37213061 |
| | Prevalence of apparent treatment-resistant hypertension among individuals with CKD. | Q37246940 |
| | A randomized trial of dietary sodium restriction in CKD | Q37340221 |
| | Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion | Q37356547 |
| | Should diuretics always be included as initial antihypertensive management in early-stage CKD? | Q37534067 |
| | Mineralocorticoid receptor blockade in chronic kidney disease | Q37861583 |
| | The double challenge of resistant hypertension and chronic kidney disease | Q38623743 |
| | Recognition and Management of Resistant Hypertension | Q38789707 |
| | The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association | Q39209456 |
| | Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. | Q40057422 |
| | Control of hypertension in adults with chronic kidney disease in the United States | Q40428173 |
| | Pathogenesis of hypertension: interactions among sodium, potassium, and aldosterone | Q43132933 |
| | Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease | Q43537658 |
| | The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5. | Q44462069 |
| | Role of excess volume in the pathophysiology of hypertension in chronic kidney disease | Q44609798 |
| | Performance of GFR estimating equations in African Europeans: basis for a lower race-ethnicity factor than in African Americans. | Q45735928 |
| | Prevalence of resistant hypertension in the United States, 2003-2008. | Q46098455 |
| | External validation and comparison of formulae estimating 24-h sodium intake from a fasting morning urine sample | Q47678198 |
| | Associations of proteinuria, fluid volume imbalance, and body mass index with circadian ambulatory blood pressure in chronic kidney disease patients | Q48212352 |
| | Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients | Q48481445 |
| | Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). | Q49791298 |
| | 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clini | Q50043295 |
| | Treatment of Disorders of Sodium Balance in Chronic Kidney Disease | Q50068237 |
| | Early changes in bioelectrical estimates of body composition in chronic kidney disease. | Q51810791 |
| | Resistant and undertreated hypertension in patients with chronic kidney disease: data from the PATRIOTIC survey. | Q52672180 |
| | Factors Associated With Hypertension Control in US Adults Using 2017 ACC/AHA Guidelines: National Health and Nutrition Examination Survey 1999-2016 | Q64138030 |
| | Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake | Q69904534 |
| | Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease | Q80807193 |
| | Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study | Q84447412 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | e010278 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study | |
| P478 | volume | 7 | |